Has the French Pharma Industry valuation changed over the past few years?

Investors are optimistic on the French Pharmaceuticals industry, and appear confident in long term growth rates. The industry is trading at a PE ratio of 24.3x which is higher than its 3-year average PE of 20.4x. The 3-year average PS ratio of 2.4x is higher than the industry's current PS ratio of 1.9x.

Which industries have driven the changes within the French Healthcare industry?

There are no additional sub-industries under this industry.

French (CAC) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 05 Aug 2026	€106.1b	€56.5b	€4.4b	18.7x	24.3x	1.9x
Fri, 03 Jul 2026	€108.6b	€54.6b	€5.3b	18.4x	20.5x	2x
Sun, 31 May 2026	€107.7b	€54.6b	€5.3b	18.7x	20.3x	2x
Tue, 28 Apr 2026	€113.4b	€54.0b	€5.4b	19.3x	21x	2.1x
Thu, 26 Mar 2026	€113.6b	€54.0b	€5.4b	19.7x	21x	2.1x
Sat, 21 Feb 2026	€113.8b	€54.0b	€5.5b	23.2x	20.8x	2.1x
Mon, 19 Jan 2026	€113.4b	€53.0b	€7.0b	22.5x	16.3x	2.1x
Wed, 17 Dec 2025	€113.0b	€53.0b	€7.0b	21.7x	16.2x	2.1x
Fri, 14 Nov 2025	€125.4b	€53.0b	€7.0b	22.5x	18x	2.4x
Sun, 12 Oct 2025	€115.3b	€52.9b	€6.9b	19.5x	16.7x	2.2x
Tue, 09 Sep 2025	€110.6b	€52.8b	€6.9b	18.7x	16x	2.1x
Thu, 07 Aug 2025	€110.1b	€52.8b	€6.9b	18.9x	15.9x	2.1x
Sat, 05 Jul 2025	€114.4b	€52.1b	€6.7b	19.5x	17.2x	2.2x
Mon, 02 Jun 2025	€119.6b	€52.1b	€6.7b	19.2x	18x	2.3x
Wed, 30 Apr 2025	€127.7b	€52.1b	€6.7b	18.5x	19.2x	2.5x
Fri, 28 Mar 2025	€137.6b	€51.2b	€5.9b	18.5x	23.1x	2.7x
Sun, 23 Feb 2025	€143.8b	€51.2b	€5.8b	18.5x	24.9x	2.8x
Tue, 21 Jan 2025	€137.6b	€55.2b	€5.1b	18.2x	27x	2.5x
Thu, 19 Dec 2024	€128.3b	€55.2b	€5.1b	19.3x	25.2x	2.3x
Sat, 16 Nov 2024	€127.9b	€55.2b	€5.1b	20.6x	25.1x	2.3x
Mon, 14 Oct 2024	€140.1b	€53.8b	€4.8b	22.6x	29.2x	2.6x
Wed, 11 Sep 2024	€146.2b	€53.8b	€4.8b	20.5x	30.5x	2.7x
Fri, 09 Aug 2024	€133.1b	€53.8b	€4.8b	20.3x	27.7x	2.5x
Sun, 07 Jul 2024	€127.8b	€52.9b	€5.2b	20.1x	24.7x	2.4x
Tue, 04 Jun 2024	€127.9b	€52.9b	€5.2b	22x	24.7x	2.4x
Thu, 02 May 2024	€130.6b	€52.9b	€5.2b	20.1x	25.2x	2.5x
Sat, 30 Mar 2024	€127.6b	€52.7b	€6.0b	21x	21.1x	2.4x
Mon, 26 Feb 2024	€126.1b	€53.0b	€6.3b	20.4x	20.1x	2.4x
Wed, 24 Jan 2024	€130.3b	€52.2b	€9.7b	20.2x	13.4x	2.5x
Fri, 22 Dec 2023	€125.8b	€52.2b	€9.7b	18.7x	12.9x	2.4x
Sun, 19 Nov 2023	€121.1b	€52.2b	€9.7b	16.9x	12.5x	2.3x
Tue, 17 Oct 2023	€144.5b	€52.6b	€9.3b	17.5x	15.6x	2.7x
Thu, 14 Sep 2023	€143.1b	€52.6b	€9.3b	18.9x	15.4x	2.7x
Sat, 12 Aug 2023	€137.1b	€52.6b	€9.3b	21.5x	14.8x	2.6x


FR Market	1.32%
Healthcare	-2.62%
Pharma	-5.81%
Pharma	-5.81%

Company	Last Price	7D	1Y	Valuation
BOI Boiron	€27.80	1.8% +€8.7m	30.8%	PE14.8x
ALTHX THX Pharma Société Anonyme	€4.52	14.7% +€8.0m	37.0%	PS77.4x
AB AB Science	€0.65	13.9% +€6.3m	-51.0%	PS44.2x
ALDVI Advicenne	€1.64	2.5% +€581.9k	37.8%	PS3.7x

Announcement • 7h

Sanofi Receives European Commission Approval For MenQuadfi Extension To Infants From Six Weeks Of Age Against Invasive Meningococcal Disease

Sanofi announced that the European Commission (EC) has approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age to help protect against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. MenQuadfi was previously approved in the EU for use in individuals aged 12 months and older. The expanded indication follows the positive opinion adopted by the Committee for Medicinal Products for Human Use on June 25, 2026. Invasive meningococcal disease is a life-threatening bacterial infection that can progress rapidly, with patients potentially deteriorating from the onset of symptoms to death within 24 hours. Infants are among the populations at highest risk for invasive meningococcal disease, facing high rates of mortality and severe long-term complications, including limb amputation, hearing loss, and neurological damage. Even with appropriate treatment, invasive meningococcal disease carries a case fatality rate of approximately 10–15%, and up to 20% of survivors experience permanent complications. Although serogroup A is now rarely reported in the EU, serogroups C, W, and Y remain responsible for a significant share of invasive meningococcal disease cases across Europe, reinforcing the importance for broad protection against these four serogroups from an early age. With this approval, MenQuadfi provides healthcare professionals in the EU with an additional option for vaccinating infants against invasive meningococcal disease from as early as six weeks of age. This expanded indication, aligned with routine infant immunization schedules, is supported by MenQuadfi's demonstrated immunogenicity data. This milestone embodies Sanofi's contribution, fighting against invasive meningococcal disease, a devastating disease, by expanding vaccine access to the most vulnerable populations across the EU. The EU approval is supported by comprehensive data from the MET58 pivotal clinical study, which evaluated the immunogenicity, safety, and tolerability of MenQuadfi in infants from six weeks of age. MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) is indicated for active immunization of individuals six weeks of age and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. MenQuadfi benefits from a strong track record of clinical data in infants with more than 6,000 infants studied across 11 countries and multiple immunization schedules. The new dose regimen approved for those starting vaccination from six weeks of age is aligned with routine pediatric vaccination schedules. The approved dosing regimens include: 2+1 schedule for infants from six weeks of age, aligned with standard EU immunization schedules. Two doses (each 0.5mL) should be administered with an interval of at least two months. One dose (booster) should be given in the second year of life (from 12 months of age) and at least two months from the last dose. For infants expected to be at increased risk of invasive meningococcal disease due to serogroup A exposure, a 3+1 schedule may be considered. Three doses primary series at two, four and six months followed by one booster dose from 12 months of age. Single dose for individuals 12 months of age and older. In infants, MenQuadfi can be co-administered with combined diphtheria - tetanus - acellular pertussis (DTaP) - inactivated poliovirus (IPV) - hepatitis B (HepB) - Haemophilus influenzae type b (Hib) vaccine (DTaP-IPV-HepB-Hib), rotavirus vaccine (live attenuated) and with 10-valent pneumococcal conjugate vaccine (PCV10). The safety and immunogenicity profile have been established across a broad age range, from six weeks of age through adulthood. MenQuadfi is well tolerated, with a safety profile comparable to other MenACWY vaccines currently licensed. The Paediatric Investigation Plan compliance statement has been received from the European Medicines Agency, marking the completion of all pediatric post-licensure commitments linked to MenQuadfi's initial marketing authorization. MenQuadfi is approved in the EU, US, and multiple other countries.

French (CAC) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Sanofi Receives European Commission Approval For MenQuadfi Extension To Infants From Six Weeks Of Age Against Invasive Meningococcal Disease

EAPI: Reset Expectations And Lower P E Multiple Could Support Rebound

IPN: Oncology And Rare Disease Pipeline Offsets Somatuline Competition Concerns

AB Science S.A. to Report First Half, 2026 Results on Sep 30, 2026

Medincell Announces Board Resignations

Virbac Maintains 2026 Growth Guidance as H1 Revenue Rises 7.4% on Key Platforms

Advicenne Announces Unlimited Renewal of Marketing Authorization for Sibnayal in United Kingdom

THX Pharma Announces Appointment of Sophie Jacq Lapointe to Board of Directors

Upcoming dividend of €1.35 per share

Dividend increased to €0.93